started · updated
Tirzepatide discontinuation linked to psychiatric symptoms in clinical report
A clinical report published in The Primary Care Companion for CNS Disorders describes two cases where patients experienced severe psychiatric symptoms after abruptly stopping tirzepatide, a GLP-1 receptor agonist used for type 2 diabetes and weight loss.
The first case involved a 61-year-old man who developed psychosis, including auditory and visual hallucinations, paranoia, and Cotard delusion, a rare condition where a person believes they are dead or missing internal organs. He had stopped the medication in August 2025 due to nausea.
The second case involved a 52-year-old man who experienced a manic episode characterized by impulsivity, irritability, grandiosity, and disorganized speech. This patient had stopped treatment after losing approximately 45 kilograms in six months. Researchers noted complicating factors in this case, including increased cannabis use and low vitamin B12 levels.
While the researchers suggest that stopping the medication may contribute to acute mood disorders or psychotic symptoms in vulnerable individuals, they emphasize that these two cases do not prove a direct causal link, as other underlying health factors and nutritional deficiencies may have played a role.
Entities
Mounjaro · Mounjaro · Taiwan · The Primary Care Companion for CNS Disorders · The Primary Care Companion for Central Nervous System Disorders · Tirzepatide · University of Pennsylvania · Zepbound · Zepbound · tirzepatide · tirzepatide